NCT01585675 Specimen Banking From Patients With Lung Cancer
| NCT ID | NCT01585675 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Lung Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2005-11-03 |
| Primary Completion | 2035-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2005-11-03 with a primary completion date of 2035-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of the protocol is to develop a comprehensive specimen banking program from patients with lung cancer for future translation research, which will enable the investigators to detect lung cancer earlier, develop better therapies and explore screening and prevention strategies.
Eligibility Criteria
Inclusion Criteria: 1. Subjects who are undergoing further testing for the diagnosis or treatment of lung cancer. 2. Oral and written informed consent Exclusion Criteria: 1\. Any individual who does not give oral and written consent for participation
Contact & Investigator
Adriaan VanBokhoven, PhD
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT01585675 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Lung Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01585675 currently recruiting?
Yes, NCT01585675 is actively recruiting participants. Contact the research team at brandi.kubala@cuanschutz.edu for enrollment information.
Where is the NCT01585675 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT01585675 clinical trial?
NCT01585675 is sponsored by University of Colorado, Denver. The principal investigator is Adriaan VanBokhoven, PhD at University of Colorado, Denver. The trial plans to enroll 2,000 participants.